|
Goserelin
resources
|
|
|
|
|
|
DRUG INFO
Goserelin
Drug Name:
Goserelin
Indication: Breast cancer; Prostate carcinoma; Endometriosis
Pharmacology: The pharmacokinetics of ZOLADEX have been determined in both male and female healthy volunteers and patients. In these studies, ZOLADEX was administered as a single 250æg (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.
Mechanism Of Action: ZOLADEX is a synthetic decapeptide analogue of LHRH. ZOLADEX acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.
Drug Category: Antineoplastic Agents; Unclassified Therapeutic Agents (92:00.00); ATC:L02AE03
Brand Names/Synonyms: Goserelin acetate; Goserelin acetate (JAN/USP); Zoladex
Dosage Forms: supplied as a sterile and totally biodegradable D,L-lactic and glycolic acids copolymer (13.3-14.3 mg/dose) impregnated with goserelin acetate equivalent to 3.6 mg of goserelin in a disposable syringe device fitted with a 16-gauge hypodermic needle
Absorption: inactive orally, rapidly absorbed following subcutaneous administration
Interactions: No formal drug-drug interaction studies have been performed. No confirmed interactions have been reported
between ZOLADEX and other drugs
Chemical IUPAC Name: N-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-(carbamoylaminocarbamoyl)pyrrolidin-1-yl]carbonyl-4-guanidino-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]-2-tert-butoxy-ethyl]carbamoyl]-2-(4-hydroxyphenyl)-ethyl]carbamoyl]-2-hydroxy-ethyl]carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-5-oxo-pyrrolidine-2-carboxamide
Chemical Formula: C59H84N18O14
Half Life: 4-5 hours
Drug Type: Approved Drug
# Accession No: BIOD00113
CAS Registry Number: 65807-02-5
|
|
|
|
|
|
Goserelin News
(When available)
Pharmac relents on Zoladex Dec 19, 2005
National Business Review, The drug, sold as Zoladex by pharmaceutical company AstraZeneca, is being used by more than 1,000 late-stage prostate cancer patients and by other patients ...
Zoladex controversy 'could have been avoided' Dec 19, 2005
Stuff.co.nz, Pharmac could have avoided the controversy over the drug Zoladex if its cancer specialist committee had been consulted over the decision to cut the subsidy ...
Pharmac and drug company in talks over Zoladex Dec 18, 2005
Radio New Zealand, ...the market. Astra Zeneca withdrew Zoladex after Pharmac reduced subsidies for the treatment dose for prostate cancer. However the ...
Zoladex back on PHARMAC list Dec 18, 2005
Newstalk ZB, Sufferers of prostate and breast cancer will still be able to get the drug Zoladex. Pharmaceutical company AstraZeneca withdrew ...
Drug company will continue to supply Zoladex, after talks Dec 18, 2005
Radio New Zealand, ...drug. Astra Zeneca withdrew the drug Zoladex altogether, after Pharmac reduced subsidies for the treatment dose for prostate cancer. ...
AstraZeneca finalises long-term Zoladex supply Dec 22, 2005
Scoop.co.nz (press release), ...an agreement with the Pharmaceutical Management Agency of New Zealand (PHARMAC) for the long-term supply of its prostate and breast cancer medicine Zoladex®. ...
Zoladex deal confirmed by Pharmac Dec 22, 2005
Radio New Zealand, The country's drug buying agency Pharmac has confirmed it has finalised an agreement to continue funding the breast and prostate cancer drug Zoladex. ...
Deal reached over cancer drug Dec 19, 2005
TVNZ, Astra Zeneca withdrew the drug Zoladex altogether after Pharmac reduced subsidies for the treatment dose for prostate cancer by 20%. ...
Astrazeneca to resupply cancer drug to patients Dec 19, 2005
Stuff.co.nz, AstraZeneca has reached agreement with government drug-buying agency Pharmac to resupply cancer drug Zoladex to New Zealand patients, the drug firm said today. ...
MP calls for look at Pharmac decision making process Dec 19, 2005
Radio New Zealand, Government drug funding agency Pharmac to look seriously at its decision making process following an outcry when breast cancer treatment Zoladex was removed ...
DELIVERING NEWS AND OPINION SINCE MAY 9, 2005 Dec 18, 2005
Huffington Post, On December 15, 2005, AstraZeneca, the big pharmaceutical company, announced it would pull its cancer drug Zoladex from the market in New Zealand. ...
Pharmac says comfortable with process over cancer drug Dec 20, 2005
Radio New Zealand, Astra Zeneca withdrew Zoladex after Pharmac reduced subsidies for the treatment dose for prostate cancer, but a verbal agreement was reached on Monday to ...
Goserelin to remain available to NZers Dec 18, 2005
Scoop.co.nz (press release), People with prostate cancer and breast cancer will continue to have fully funded access to the hormonal treatment goserelin (Zoladex) following an agreement ...
Pharmac must look seriously at decision-making Dec 19, 2005
Scoop.co.nz (press release), Health spokeswoman, Jackie Blue, is pleased that negotiations between Pharmac and pharmaceutical company AstraZeneca have resulted in Zoladex staying on the ...
|
|
|
